Korro Bio’s corporate headquarters are located at One Kendall Square, Building 600-700, Suite 6-401, Cambridge, MA 02139.

Korro Bio’s common stock is listed on the Nasdaq Global Select Market under the symbol “KRRO”.

Korro Bio’s merger agreement closed on November 3, 2023, and shares began trading November 6, 2023.

Korro Bio was founded in 2018.

Korro Bio’s fiscal year ends December 31.

Korro Bio does not offer a direct stock purchase program.

Korro Bio does not expect to pay dividends in the foreseeable future.

The legal counsel for Korro Bio is Goodwin Procter, LLP.

Korro Bio’s registered public accountant is Ernst and Young, LLP.

Korro Bio’s transfer agent is Computershare Limited.

Please contact IR@korrobio.com.

To receive email alerts on Korro Bio, visit the “Email Alerts” portion of our Investors Relations website.